Verve Therapeutics Inc (VERV)

$6.91 0.00 (0.00%)

16:00 EDT VERV Stock Quote Delayed 30 Minutes

3 Stocks That Could Be the Next Big Thing in Gene Editing

By Ian Cooper, InvestorPlace Contributor Mar 21, 2024

Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

3 Gene Editing Stocks With Unprecedented Surge Potential

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.)

Day's Range -

52-Week Range $6.42 - $21.42

Dividend & Yield N/A (N/A)

VERV Stock Predictions, Articles, and Verve Therapeutics Inc News

From InvestorPlace
From the Web

7 Mighty Healthcare Stocks Changing the Game of Medicine

By Josh Enomoto, InvestorPlace Contributor Jan 17, 2024

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily,…

3 Stocks to Buy in the Booming Field of Gene Editing

By Chris Markoch, InvestorPlace Contributor Jan 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Nov 29, 2023

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

Why Is Verve Therapeutics (VERV) Stock Down 39% Today?

By William White, InvestorPlace Writer Nov 13, 2023

Verve Therapeutics stock is falling on Monday even after the company posted promising interim data from a Phase 1b clinical trial.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Nov 13, 2023

Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning!

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On

By Yiannis Zourmpanos, InvestorPlace Contributor Nov 1, 2023

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Why Is Verve Therapeutics (VERV) Stock Down 28% Today?

By William White, InvestorPlace Writer Nov 7, 2022

Verve Therapeutics (VERV) stock is taking a beating on Monday following bad news from the U.S. Food and Drug Administration (FDA).

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Nov 7, 2022

Good morning, investor! We're diving into the biggest pre-market stock movers for Monday as we get ready for another week of trading!

5 Top Stocks Cathie Wood Is Buying This Week

By Eddie Pan, InvestorPlace Financial News Writer Sep 30, 2022

There's a new Ark fund in town, and its name is the ARK Venture Fund. It will capitalize on democratizing private investments to the public.

The Top 5 Stocks Cathie Wood Is Buying This Week

By Eddie Pan, InvestorPlace Financial News Writer Sep 23, 2022

Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.

5 Top Stocks Cathie Wood Is Buying Right Now

By Eddie Pan, InvestorPlace Financial News Writer Sep 19, 2022

Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jul 21, 2022

Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers traders need to know about!

After a Serious Setback, Is Verve Therapeutics a Buy?

From The Motley Fool Apr 6, 2024

There are a few silver linings at play here.

Verve Therapeutics (NASDAQ:VERV) Plunges on Trial Halt

From TipRanks Apr 2, 2024

Verve Therapeutics (NASDAQ:VERV) shares plunged by nearly 33% in the early session today after the clinical-stage gene editing company halted patient enrollments in...

Verve Pauses Gene-Editing Trial for High Cholesterol Treatment

From Bloomberg Apr 2, 2024

Verve Therapeutics Inc. shares tumbled in premarket trading after it cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine.

Beam stock jumps as Eli Lilly deal brings Q4 beat (NASDAQ:BEAM)

From Seeking Alpha Feb 27, 2024

Beam Therapeutics (BEAM) stock gains as the company reports profits in Q4 after boosting revenue thanks to a collaboration deal with Eli Lilly (LLY). Read more here.

Verve Therapeutics GAAP EPS of -$0.69 beats by $0.13, revenue of $5.14M beats by $3.97M (NASDAQ:VERV)

From Seeking Alpha Feb 27, 2024

Verve Therapeutics reports better-than-expected Q4 financial results, with higher revenue and a cash runway extending into late 2026.

Why Verve Therapeutics Stock Crashed as Much as 30% This Week

From The Motley Fool Nov 17, 2023

There was a concerning development in the company's clinical trials.

Verve Therapeutics Inc (VERV)

3 Stocks That Could Be the Next Big Thing in Gene Editing

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

3 Gene Editing Stocks With Unprecedented Surge Potential

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Verve Therapeutics Inc (VERV)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

VERV Stock Predictions, Articles, and Verve Therapeutics Inc News

Subscriber Sign in